Regulated information

Number of shares composing current share capital and total number of voting rights as of 31 October 2026

Paris, 10 November 2026

Information about the total number of voting rights and shares pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the AMF General Regulations.

Date Number of shares composing current share capital Total number of
voting rights
31 October 2026 739,264,232   Gross: 821,069,912

Press contacts:

Jean-Baptiste Froville _ +33 1 58 98 68 00 _ jean-baptiste.froville@socgen.com  
Fanny Rouby _ +33 1 57 29 11 12 _ fanny.rouby@socgen.com

Societe Generale

Societe Generale is a top-tier European Bank with around 110,000 employees serving 27 million clients in 58 countries across the world. We have been supporting the development of our economies for over 160 years, providing our corporate, institutional, and individual clients with a wide array of value-added advisory and financial solutions. Our long-lasting and trusted relationships with the clients, our cutting-edge expertise, our unique innovation, our ESG capabilities and leading franchises are part of our DNA and serve our most essential objective – to deliver sustainable value creation for all our stakeholders.

The Group runs three complementary sets of businesses, embedding ESG offerings for all its clients:

  • French Retail, Private Banking and Insurance, with leading retail bank SG and insurance franchise, premium private banking services, and the leading digital bank BoursoBank;
  • Global Banking and Investor Solutions, a top tier wholesale bank offering tailored-made solutions with distinctive global leadership in equity derivatives and structured finance;
  • Mobility, International Retail Banking and Financial Services, comprising well-established universal banks (in Czech Republic, Romania and several African countries), Ayvens, a global player in sustainable mobility, as well as specialized financing activities.

Committed to building together with its clients a better and sustainable future, Societe Generale aims to be a leading partner in the environmental transition and sustainability overall. The Group is included in the principal socially responsible investment indices: DJSI (Europe), FTSE4Good (Global and Europe), Bloomberg Gender-Equality Index, Refinitiv Diversity and Inclusion Index, Euronext Vigeo (Europe and Eurozone), STOXX Global ESG Leaders indexes, and the MSCI Low Carbon Leaders Index (World and Europe).

In case of doubt regarding the authenticity of this press release, please go to the end of the Group News page on societegenerale.com website where official press releases sent by Societe Generale can be certified using blockchain technology. A link will allow you to check the document’s legitimacy directly on the web page.

For more information, you can follow us on X @societegenerale or visit our website societegenerale.com.

Attachment

DANONE

French Société anonyme with a capital of €170,834,294.25
Registered Office: 59-61, rue La Fayette, 75009 Paris.
Registered with the Paris Commerce and Company Registry under number 552 032 534

Information on the total number of voting rights and shares

in compliance with Article L. 233-8 II of the French Commercial Code and with Article 223-16 of the General Regulation of the Financial Markets Authority (AMF- Autorité des Marchés Financiers)

Date Total number of shares Total number of voting rights
31/10/2026 683,337,177 Total number of theoretical voting rights(1): 723,102,859

Total number of exercisable voting rights(2): 683,861,176

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

(2) The total number of exercisable voting rights (or ”net” voting rights) is calculated without taking into account the shares with suspended voting rights. It is published to ensure that the public is properly informed in accordance with the recommendation made by the AMF on July 17, 2007.

Attachment

NORWALK, Conn., Nov. 10, 2026 (GLOBE NEWSWIRE) — FactSet, a leading global intelligence and AI solutions provider to the financial markets, has partnered with Carbon Arc, the neutral data layer for the AI economy, to bring governed access to more than 60 alternative data providers and over 500 distinct data assets into FactSet’s Workstation and Model Context Protocol (MCP) ecosystem.

Through this partnership, Carbon Arc’s alternative data will be embedded directly into FactSet’s platform and workflows, giving investment professionals a more complete picture of the factors shaping business performance. The integration spans a broad range of data sets, including credit card transactions, retail foot traffic, digital advertising activity, ecommerce trends, web and app traffic, and housing permits, enabling analysts and portfolio managers to identify shifts in consumer demand, track competitive positioning, and detect early signals of changing market conditions.

The integrated solution is designed to deliver across three core capabilities:

  • Expanded Data Access: Content from more than 60 alternative data providers and over 500 data assets will be accessible within FactSet’s workflow solutions, giving investment professionals a broader and more diverse set of insights for fundamental and quantitative analysis.
  • Seamless Workflow Integration: Available as an optional add-on via single sign-on, the data will be accessible through FactSet’s Workstation and its MCP integrations with major hyperscalers and leading AI labs, allowing clients to incorporate alternative data into existing research and investment processes.
  • AI-Ready Intelligence: By connecting Carbon Arc’s alternative data to FactSet’s MCP ecosystem, the partnership positions clients to take full advantage of AI-powered tools and workflows, delivering faster, more actionable insights across industries, geographies and investment strategies.

“Investment professionals have always relied on FactSet for our high quality trusted financial data as the foundation for every stage of the investment and dealmaking lifecycle,” said John Costigan, Co-Head of Product at FactSet. “By integrating Carbon Arc’s catalogue of alternative data assets, we are meaningfully expanding the depth and breadth of insights our clients can unlock with FactSet Intelligence.”

“The model isn’t a bottleneck anymore. The data layer is,” said Kirk McKeown, Founder and Chief Executive Officer of Carbon Arc. “With the Carbon Arc platform available in FactSet’s AI ecosystem, its clients get governed access to over 500 real-world data assets in the workflows they already use. We’re excited to power differentiated research, investing and advisory use cases.”

About FactSet

FactSet (NYSE:FDS | NASDAQ:FDS) supercharges financial intelligence, offering enterprise data and information solutions that help our clients maximize their potential. Our cutting-edge digital platform seamlessly integrates proprietary financial data, client datasets, third-party sources, and flexible technology to deliver tailored solutions across the buy side, sell side, wealth management, private equity, and corporate sectors. With over 48 years of expertise, a presence in 20 countries, and extensive multi-asset class coverage, we leverage advanced data connectivity alongside AI and next-generation tools to streamline workflows, drive productivity, and enable smarter, faster decision-making. Serving more than 9,200 global clients and over 260,000 individual users, FactSet is a member of the S&P 500 dedicated to innovation and long-term client success. Learn more at www.factset.com and follow us on X and LinkedIn.

FactSet Investor Relations:
Kevin Toomey
+1.212.209.5259
Kevin.toomey@factset.com

FactSet Media Relations:

Alexandra Shevchenko
Oleksandra.shevchenko@factset.com

About Carbon Arc

Founded in 2021, Carbon Arc is the neutral data layer for the AI economy: the missing infrastructure between private enterprise data and AI inference. Carbon Arc finds hard-to-source real-world company data, clears it through a compliance layer, and delivers it on demand. The Carbon Arc platform offers 500+ data assets. As models converge on speed and price, the data feeding each decision becomes the edge.

Carbon Arc Media Relations:
Pro-carbonarc@prosek.com

abc arbitrage: The calendar of financial events for the year 2027

ABC arbitrage Group hereby informs you of the key dates in the financial calendar for the 2027 financial year.

Registered name of the issuer:
ABC arbitrage – 18 rue du Quatre Septembre – 75002 Paris.

Upcoming financial events Date
Announcement of the 2026 annual results Tuesday 23 March 2027
2027 Annual general meeting Friday 4 June 2027
Announcement of the 2027 half-year results Tuesday 21 September 2027

N.B.: The press releases will be published on the dates at 07:00am, before the markets open.
N.B. 2: For the ex-dividend dates, please refer to the calendar on the website.

Furthermore, as for the 2026 financial year, ABC arbitrage Group has chosen not to publish any quarterly or interim information for the 2027 financial year (as a consequence of the amendments to Directive 2004/109/EC, known as the “Transparency” Directive, and in accordance with the recommendation of the Autorité des Marchés Financiers on this matter (DOC-2015-03)).

Contacts : abc-arbitrage.com
Relations actionnaires : actionnaires@abc-arbitrage.com
Relations presse: VERBATEE / v.sabineu@verbatee.com
EURONEXT Paris – Compartiment B
ISIN : FR0004040608
Reuters  BITI.PA / Bloomberg ABCA FP

Attachment

Disclosure of Share Capital and Voting Rights Outstanding
as of October 31, 2026

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Paris, France (November 10, 2026 – 6:00 pm) – As of October 31, 2026, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.

  October 31, 2026
Shares outstanding 464,247,548
Number of real voting rights (excluding treasury shares) 458,376,127
Theoretical number of voting rights (including treasury shares) 464,247,548

It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article 23 of EssilorLuxottica’s by-laws1.

1EssilorLuxottica’s by-laws are available on the Company’s website under the section Governance / Publications.

Attachment

News Highlights:

  • 6th Gen AMD EPYC SP7 CPU-based platforms are now shipping from leading server OEMs and ODMs.
  • 6th Gen EPYC CPUs are expected to power cloud instances across all major, global cloud service providers, with recent announcements from Microsoft Azure and OCI showcasing leadership agent orchestration, concurrent agent sandboxes, as well as web and enterprise applications.
  • Powered by the new AMD “Zen 6” architecture, 6th Gen EPYC CPUs deliver a broad portfolio of workload-optimized server CPUs spanning agentic AI, enterprise, cloud computing, HPC and general-purpose computing.

SANTA CLARA, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced the general availability of the 6th Gen AMD EPYC™ server SP7 processors, based on the new “Zen 6” architecture, extending its historical server CPU performance leadership as AI creates new demands across the data center. Systems powered by the new CPUs are shipping from leading server vendors, and cloud instances from Microsoft Azure and OCI will be generally available soon.

Across five generations, AMD EPYC processors have repeatedly raised the standard for server CPU performance, energy efficiency and platform choice, culminating in 5th Gen AMD EPYC™ processors becoming the fastest-ramping and highest-volume EPYC generation in AMD history. Now, 6th Gen AMD EPYC server CPUs extend AMD CPU leadership, running AI agents, accelerated infrastructure and critical enterprise applications, helping customers expand computing capacity that runs their businesses.

More: AMD Launches 6th Gen AMD EPYC Embedded Processors, Extending CPU Leadership (News) | AMD In Depth: EPYC ‘Venice’ (Press Kit, Videos, Photos)

“AI is significantly expanding the role of the CPU across every layer of the data center,” said Dan McNamara, senior vice president and general manager, Compute and Enterprise AI, AMD. “With 6th Gen AMD EPYC, customers can standardize on the proven x86 foundation while choosing a workload-optimized solution to run more agents, keep accelerated infrastructure fed, and power the business-critical applications they depend on.”

World’s Best Server CPU Portfolio for the Modern Data Center

6th Gen AMD EPYC is the world’s best server CPU portfolio,i providing a workload-optimized stack that delivers leadership performance across a diversity of applications while improving infrastructure economics and preserving the flexibility of the broad x86 ecosystem.

Agentic AI adds even more diversity to a data center as a single workflow can run agents, call models, retrieve data, execute code and interact with the databases and applications enterprises already depend on. The 6th Gen AMD EPYC portfolio is designed for that reality, matching CPU density, frequency, bandwidth and efficiency to each job while preserving one common software, security and operational foundation. That workload-optimized approach delivers advantages across critical areas including agentic AI, enterprise services and rack-scale solutions.

  • Power More Enterprise and Cloud Services: The 6th Gen AMD EPYC™ 9996 CPU is the world’s best general-purpose processor, delivering leadership performance, performance per CPU watt, performance per CPU dollar and performance per socket. An AMD EPYC 9996 CPU-based system delivers up to 3.7x more performance compared with an Nvidia Vera CPU-based system and up to 2.2x the performance and 2.0x the performance per dollar of an Intel® Xeon® 6980P system.ii For customers, that can translate into more applications, transactions and users supported by each server, helping create capacity for new workloads within existing data center power and footprint limitations.
  • Lead Across Every Tier of Agentic AI: Agentic AI infrastructure spans three distinct CPU roles – general-purpose services, GPU host nodes, and agent sandboxes – and 6th Gen AMD EPYC provides a workload-optimized processor for each. High-frequency host-node processors, with up to 5.3 GHz, can deliver up to 1.8x the LLM output throughput of previous generation EPYC processorsiii and high-density AMD EPYC processors can provide up to ~3.3x agents-per-CPU-watt advantage over Nvidia Vera and ~2.5x over Intel Xeon 6980P for hosting agent sandboxes.iv Additionally, for agent sandboxes, AMD EPYC 9996 CPU-based servers can support an estimated ~1.18x as many agents per rack within the same 35 kilowatt power envelope as systems using default power-management settings.v

The competitive choice is increasingly straightforward. With 6th Gen AMD EPYC, customers do not have to settle for a one-size-fits-all CPU in a data center that is anything but uniform. AMD EPYC delivers the performance, choice and ecosystem support needed to move AI from answers to action and prepare for what comes next.

From the Server to Rack-Scale AI

6th Gen AMD EPYC extends its leadership from individual servers to AMD Helion™ agentic AI racks, giving customers three deployment options matched to how and where they operate: AMD Helion Liquid, designed to sit side-by-side with AMD Helios™ rackscale solution in large-scale agentic AI deployments, for maximum agent density; AMD Helion Air for expanding agent capacity within existing air-cooled data centers; and AMD Helion Air Inference for combining CPU execution and local GPU inference in one rack. AMD has worked across the server ecosystem to help develop the high-density AMD Helion rack with some configurations reaching up to 73,728 threads in one rack, delivering the most agents available in a rack. Customers can choose the balance of CPU and GPU capacity, cooling and connectivity that fits their infrastructure as agent demand grows.

Broad Ecosystem Support and Availability

Systems powered by 6th Gen AMD EPYC server processors are shipping from leading server vendors:

  • Meta is working with AMD as a lead customer and has been validating 6th Gen AMD EPYC CPU-based platforms as the companies prepare for deployment at scale.
  • Microsoft Azure is bringing 6th Gen AMD EPYC to customers across the AI infrastructure stack, with Azure HDv2 now in preview for AI data processing, agentic AI and HPC; Azure HXv2 for EDA and technical computing; and Azure ND MI455X v7, based on AMD Helios, for production-scale AI inference.
  • AMD recently shared updates to its multigeneration collaboration with Oracle Cloud Infrastructure (OCI). OCI Compute E7 cloud compute instances will be powered by 6th Gen AMD EPYC server processors, supporting enterprise applications and the CPU services surrounding AI models.

With 6th Gen AMD EPYC, AMD is extending five generations of server CPU leadership into the agentic AI era; delivering more compute, better economics and more choice from the server to the rack. Across enterprise, cloud, HPC and AI infrastructure, EPYC provides a broad portfolio built for the workloads customers run today and what comes next.

Supporting Resources:

About AMD

AMD (NASDAQ: AMD) drives innovation in high-performance and AI computing to solve the world’s most important challenges. Today, AMD technology powers billions of experiences across cloud and AI infrastructure, embedded systems, AI PCs and gaming. With a broad portfolio of AI-optimized CPUs, GPUs, networking and software, AMD delivers full-stack AI solutions that provide the performance and scalability needed for a new era of intelligent computing. Learn more at www.amd.com.

CAUTIONARY STATEMENT

This press release contains forward-looking statements concerning Advanced Micro Devices, Inc. (AMD) such as the features, functionality, performance, availability, timing and expected benefits of AMD products including the 6th Gen AMD EPYC™ Server SP7 processors, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond AMD’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: impact of government actions and regulations such as export regulations, national-security-based regulations, import tariffs, trade protection measures, and licensing requirements; competitive markets in which AMD’s products are sold; the cyclical nature of the semiconductor industry; market conditions of the industries in which AMD products are sold; AMD’s ability to introduce products on a timely basis with expected features and performance levels; loss of a significant customer; economic and market uncertainty; quarterly and seasonal sales patterns; AMD’s ability to adequately protect its technology or other intellectual property; unfavorable currency exchange rate fluctuations; ability of third party manufacturers to manufacture AMD’s products on a timely basis in sufficient quantities and using competitive technologies; availability of essential equipment, materials, components (such as memory supply), substrates or manufacturing processes; ability to achieve expected manufacturing yields for AMD’s products; AMD’s ability to generate revenue from its semi-custom SoC products; potential security vulnerabilities; potential security incidents including IT outages, data loss, data breaches and cyberattacks; uncertainties involving the ordering and shipment of AMD’s products; AMD’s reliance on third-party intellectual property to design and introduce new products; AMD’s reliance on third-party companies for design, manufacture and supply of motherboards, software, memory and other computer platform components; AMD’s reliance on Microsoft and other software vendors’ support to design and develop software to run on AMD’s products; AMD’s reliance on third-party distributors and add-in-board partners; impact of modification or interruption of AMD’s internal business processes and information systems; compatibility of AMD’s products with some or all industry-standard software and hardware; costs related to defective products; failure to maintain an efficient supply chain as customer demand changes; AMD’s ability to rely on third party supply-chain logistics functions; AMD’s ability to effectively control sales of its products on the gray market; impact of climate change on AMD’s business; AMD’s ability to realize its deferred tax assets; potential tax liabilities; current and future claims and litigation; impact of environmental laws, conflict minerals related provisions and other laws or regulations; evolving expectations from governments, investors, customers and other stakeholders regarding corporate responsibility matters; issues related to the responsible use of AI; restrictions imposed by agreements governing AMD’s notes, the guarantees of Xilinx’s notes and the revolving credit agreement; AMD’s ability to satisfy financial obligations under guarantees, leases and other commercial commitments; impact of acquisitions, joint ventures and/or investments on AMD’s business and AMD’s ability to integrate acquired businesses; impact of any impairment of the combined company’s assets; political, legal and economic risks and natural disasters; future impairments of technology license purchases; AMD’s ability to attract and retain key employees; and AMD’s stock price volatility, including the potential impact on the fair value of customer warrants and AMD’s GAAP earnings. Investors are urged to review in detail the risks and uncertainties in AMD’s Securities and Exchange Commission filings, including but not limited to AMD’s most recent reports on Forms 10-K and 10-Q.

i EPYC-029E: Claim of “best CPU for cloud, enterprise, and AI” is based on AMD’s assessment of the best overall combination of projected performance, thread density, enterprise workload results, AI benchmark performance, energy efficiency, memory subsystem capabilities, I/O capabilities, process technology, and built-in security features among evaluated general-purpose enterprise server CPUs as of 7/23/2026. “Best” reflects the strongest overall combination across the evaluated cloud, enterprise, and AI criteria and does not imply leadership in every individual workload or metric. Products not available for comparable testing or not positioned as general-purpose enterprise server CPUs were not included.

ii “9xx6-004C: SPECrate®2017_int_base comparison based on published scores from www.spec.org as of 11/05/2026 and AMD internal estimates for 2P NVIDIA Vera and 2P Arm AGI as of 10/10/2026. Highest performing 2P server CPU based on the highest published 2P SPECrate®2017_int_base score and the highest published score per CPU (per socket). Results and configurations below are in the format of: [processor], [cores], [Default CPU Power or TDP], [1Ku price in USD], [score], [score / CPU W], [score / 1Ku price in USD], [score / core], [Link to score]
2P AMD EPYC 9996, 512C, 600W, $14904 USD, 5470, 9.117, 0.367, 10.68, https://www.spec.org/cpu2017/results/res2026q4/cpu2017-20261020-52013.html
2P AMD EPYC 9965, 384C, 500W, $11988 USD, 3260, 6.520, 0.272, 8.49, https://www.spec.org/cpu2017/results/res2026q4/cpu2017-20261005-51950.html
2P Intel Xeon 6990E+, 576C, 450W, $14995 USD, 3050, 6.778, 0.203, 5.30, https://www.spec.org/cpu2017/results/res2026q2/cpu2017-20260518-51499.html
2P Intel Xeon 6980P, 256C, 500W, $13955 USD, 2510, 5.020, 0.180, 9.80, https://www.spec.org/cpu2017/results/res2025q4/cpu2017-20251126-50522.html
2P NVIDIA Vera, 176C, 450W, pricing not published, AMD estimate 1459, 3.242, n/a, 8.29
2P Arm AGI, 272C, 300W, pricing not published, AMD estimate 1944, 6.480, n/a, 7.15
NVIDIA Vera and Arm AGI scores are AMD internal estimates based on AMD engineering projections and subject to change; NVIDIA Vera estimate based on published Phoronix testing, https://www.phoronix.com/review/nvidia-vera-benchmarks/. Pricing not published for NVIDIA Vera or Arm AGI. Intel CPU W and prices at https://ark.intel.com/ as of 11/05/2026.
Starting with the 6th Gen AMD EPYC™ server processor family, AMD uses Default CPU Power to describe processor power consumption, succeeding AMD’s historical TDP reference. Default CPU Power reflects total power consumed across the processor’s compute and I/O dies for the stated performance target. Default CPU Power and TDP may both serve as processor power references for product comparison, platform planning, and performance-per-watt analysis.
SPEC®, SPEC CPU®, SPECrate® and SPECint® are registered trademarks of the Standard Performance Evaluation Corporation. See www.spec.org for more information.
AMD CPU prices as of 11/05/2026.
Results may vary due to factors including system configurations, software versions and BIOS settings.”

iii 9xx6-022: Model-weight CPU-offload LLM inference output throughput comparison based on AMD internal testing measured on a PCIe Gen 5 x16 host link and estimated projected to PCIe Gen 6 x16 by host-to-GPU link bandwidth, as of 7/13/2026. Comparison is a 6th Gen AMD EPYC 96c HF processor host node (PCIe Gen 6, 5GHz) versus a 5th Gen AMD EPYC 9575F (PCIe Gen 5, 5GHz), with a 6th Gen Intel Xeon 6960P host node as a competitive reference. All measured systems were run 2-socket (full node) with SMT disabled. Workload: Qwen3-30B-A3B, BF16 weights (approximately 61 GB resident), tensor-parallel=1, 1024 input tokens, 256 output tokens, vLLM CPU-offload, median of n=3 iterations, measured on 1x NVIDIA B200. Measured Gen 5 output throughput for the 5th Gen AMD EPYC 9575F was 148.4, 114.8, 93.8, and 61.7 tokens per second at 6, 9, 12, and 20 GB of offloaded weights, with PCIe receive bandwidth pinned at 89 to 95 percent of the Gen 5 x16 ceiling and host DRAM read bandwidth below 10 percent of its 614 GB/s ceiling, establishing the PCIe link (not host memory) as the throughput limiter. Because decode is PCIe-transfer-bound, doubling host-to-GPU bandwidth (Gen 5 x16 at 64 GB/s per direction to Gen 6 x16 at 128 GB/s per direction) projects a 1.8x to 1.9x throughput ceiling for the 6th Gen AMD EPYC 96c HF processor. Measured Gen 5 output throughput for the 6th Gen Intel Xeon 6960P was 104.9 and 82.3 tokens per second at 9 and 12 GB of offloaded weights (median of n=3 iterations, same NVIDIA B200 host and vLLM configuration), versus 114.8 and 93.8 tokens per second for the 5th Gen AMD EPYC 9575F at the same offload points, so the 5th Gen AMD EPYC 9575F delivers 1.09x and 1.14x the 6th Gen Intel Xeon 6960P output throughput (up to 1.1x). Memory configuration was 24x 128 GB DDR5-6400 (AMD) and 24x 64 GB DDR5-6400 (Intel); host DRAM utilization remained below 10 percent throughout, so memory capacity was not the throughput limiter. Preliminary performance estimates based on AMD engineering projections or measurements as of 7/13/2026 and subject to change. PCIe is a registered trademark of PCI-SIG Corporation.

iv “9xx6-014B: Comparison based on published Top-of-stack core counts and CPU W, Default CPU Power for 6th Gen EPYC, and TDPs for 5th Gen EPYC, Intel® Xeon®, and Nvidia Vera for estimated Highest Agents / CPU W across AMD EPYC™ 256C at 400W, AMD EPYC™ 9965 (500W TDP), Nvidia Vera (450W TDP), ARM AGI (300W TDP), Intel® Xeon® 6980P (500W TDP), and Intel Xeon 6990E+ (450W TDP) powered servers as of 7/22/2026. 2 threads per core (SMT). 1 thread per core for ARM AGI.

Agent counts are estimates derived from available CPU thread resources used as a proxy under a consistent theoretical workload. Actual agent capacity and throughput will vary based on workload, model, memory, software, orchestration, and system configuration.

Starting with the 6th Gen AMD EPYC™ server processor family, AMD uses Default CPU Power to describe processor power consumption, succeeding AMD’s historical TDP reference. Default CPU Power reflects total power consumed across the processor’s compute and I/O dies for the stated performance target. Default CPU Power and TDP may both serve as processor power references for product comparison, platform planning, and performance-per-watt analysis. Intel Xeon TDP from ark.intel.com. Nvidia Vera TDP from https://developer.nvidia.com/blog/nvidia-vera-cpu-sets-a-new-standard-for-agentic-workloads-in-ai-factories/. ARM AGI Specifications from https://www.arm.com/products/cloud-datacenter/arm-agi-cpu#Specifications “

v 9xx6-086A: Agents per rack comparison based on AMD analysis as of November 2026 of AMD EPYC™ 9996 (256 cores, SMT on, 600W Default CPU Power) servers with 16 DDR5-8000 RDIMMs per socket in a 35 kW rack (maximum 20 servers per rack).
Default provisioning (830W combined SOC and DIMM power per socket): 16 servers per rack, 1.00x agents per rack.
UPP with a 10% lower combined SOC and DIMM power limit (747W per socket): 17.8 servers per rack, 1.11x agents per rack.
UPP with a 15% lower combined SOC and DIMM power limit (706W per socket): 18.8 servers per rack, 1.18x agents per rack.
Agents per watt with UPP: AMD EPYC 9996 (256 cores, SMT on, 600W Default CPU Power) is estimated to provide ~1.9x the agents per CPU W of Arm AGI (136 cores, 1 thread per core, 300W TDP). With UPP at a 15% lower combined SOC and DIMM power limit, the estimated agents per rack watt increase by 1.18x, for an estimated ~2.2x agents per watt advantage. Arm AGI specifications from https://www.arm.com/products/cloud-datacenter/arm-agi-cpu#Specifications.
Servers per rack are estimated by scaling the number of servers that fit in the rack power envelope inversely with the per-server power limit, without rounding to whole servers.
Estimated average per-server performance reduction of 0% at the 10% lower limit and 1% at the 15% lower limit, based on AMD internal testing of a 5th Gen AMD EPYC™ 128-core 500W processor running SPEC CPU®2017 integer workloads.
Agent counts are estimates derived from available CPU thread resources used as a proxy under a consistent theoretical workload. Actual agent capacity and throughput will vary based on workload, model, memory, software, orchestration, and system configuration.
UPP power savings and performance impact depend on measured DIMM power and will vary with workload and operating conditions. System manufacturers may vary configurations, yielding different results.
Preliminary performance estimates based on AMD engineering projections or measurements as of November 5, 2026 and subject to change. SPEC® and SPEC CPU® are registered trademarks of the Standard Performance Evaluation Corporation. See www.spec.org for more information.

CONTACT: Contact:
Aaron Grabein
AMD Communications
aaron.grabein@amd.com 

Liz Stine
AMD Investor Relations
liz.stine@amd.com 

Houston chapter of AGC cites new campus in awarding construction firm O’Donnell/Snider

Lincoln Tech’s Houston, TX Campus

Lincoln Tech's second facility in Texas is strategically located on I-45, just minutes from I-69 and in the heart of one of Houston’s busiest commercial corridors.
Lincoln Tech’s second facility in Texas is strategically located on I-45, just minutes from I-69 and in the heart of one of Houston’s busiest commercial corridors.

Lincoln Tech Houston’s Lobby and Auto Shop

The campus includes approximately 100,000 square feet of classroom and training space for programs in the automotive service, welding, HVAC-R and electrical fields.
The campus includes approximately 100,000 square feet of classroom and training space for programs in the automotive service, welding, HVAC-R and electrical fields.

Parsippany, NJ, Nov. 10, 2026 (GLOBE NEWSWIRE) — Lincoln Educational Services Corporation (NASDAQ: LINC), a national leader in specialized technical training for 80 years, announced today that its Houston, TX campus has been recognized for an industry award in design and construction. O’Donnell/Snider, the Houston-based construction firm which built the campus, received a Silver APEX Award from Houston AGC, the local chapter of the Associated General Contractors of America. AGC is the commercial construction industry’s leading national association representing general contractors, subcontractors, suppliers, and manufacturers.

Lincoln Tech’s Houston campus, which celebrated its grand opening earlier this year and was built by O’Donnell/Snider in 2025, was granted the award in AGC’s Higher Education category.

“As Lincoln Tech expands its presence across the country, we value partnerships with organizations like O’Donnell/Snider to ensure our students will be training in some of the finest facilities anywhere,” says Scott Shaw, Lincoln Tech’s President and CEO. “Building a campus to meet the needs of a diverse group of students, training for future careers in an equally diverse range of industries, is no small feat – and we could not be prouder or more grateful for the work performed by Adam Boak and the entire O’Donnell/Snider team.”

“Receiving an AGC Houston APEX Award for Lincoln Tech’s Houston campus is a tremendous honor and reflects the commitment, collaboration, and execution of the entire project team,” adds Boak, Senior Project Manager at O’Donnell/Snider Construction. “Successfully delivering an educational facility requires thoughtful planning, proactive coordination and a clear understanding of the client’s goals. Working closely with Lincoln Tech and our project partners, we are proud to have delivered a facility that supports hands-on technical education and creates opportunities for students entering the skilled trades.”

Boak oversaw construction of the campus and helped coordinate the collaborative effort required to deliver the project. His leadership throughout construction supported the execution of a complex renovation and helped bring Lincoln Tech’s vision for the Houston campus to life.

Gary Musciano of Herbst-Musciano Architects contributed to the architectural vision and design coordination for the campus, helping transform the former Amazon facility into a purpose-built technical training environment. His work helped align the building design with Lincoln Tech’s instructional programs and the specialized needs of students training in the transportation and skilled trades industries.

The Houston campus, Lincoln Tech’s second facility in Texas, is at the site of a converted former Amazon facility at 2000 South Lockwood Drive. It includes approximately 100,000 square feet of classroom and training space for programs in the automotive service, welding, HVAC-R and electrical fields. The campus is strategically located on I-45, just minutes from I-69 and in the heart of one of Houston’s busiest commercial corridors.

###

About Lincoln Educational Services Corporation

Lincoln Educational Services Corporation is a leading provider of diversified career-oriented post-secondary education. Lincoln offers recent high school graduates and working adults career-oriented programs in skilled trades, automotive, health sciences and information technology. Lincoln has provided the workforce with skilled technicians since its inception in 1946.

Lincoln currently operates 23 campuses in 12 states under 3 brands: Lincoln College of Technology, Lincoln Technical Institute and Nashville Auto Diesel College. For more information, visit www.lincolntech.edu. 

Attachments

CONTACT: Scott Watkins, VP Marketing
Lincoln Tech
973.766.9656 
Swatkins@lincolntech.edu

  • Updated clinical data from three iadademstat studies to be presented at ASH 2026, including encouraging results from ALICE-2 in first-line AML (95% ORR, 84% CRc and 74% CR) and FRIDA in relapsed/refractory FLT3-mutated AML (67% CRc rate at the recommended Phase II dose)
  • New VIVALDI study evaluating iadademstat in first-line AML authorized in Spain, complementing preparations for the planned ALICE-3 Phase III program
  • Vafidemstat EVOLUTION Phase IIb trial in schizophrenia continues enrolling patients across several European countries
  • Vafidemstat Phase III PORTICO-2 trial in aggression in borderline personality disorder (BPD): Preparatory activities progress, with a planned FDA Type C meeting
  • Vafidemstat Phase II HOPE-2 trial in Phelan-McDermid syndrome (PMS) receives authorization to initiate in Spain
  • Cash position as of September 30, 2026, was $21.7 million (€19.1 million)

MADRID and CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended September 30, 2026, and provided a corporate update on recent developments.

“Since our last results update, Oryzon has continued to build the clinical evidence needed to advance our key development programs,” said Dr. Carlos Buesa, Oryzon’s Chief Executive Officer. “The three iadademstat abstracts accepted for ASH 2026 add to the growing body of clinical evidence supporting the activity of iadademstat across hematological malignancies. We are particularly encouraged by the high remission rates and promising survival results observed with iadademstat in combination with azacitidine and venetoclax in the Phase Ib ALICE-2 study in newly diagnosed AML. We look forward to presenting updated data at ASH in December.”

“Building on the ALICE-2 findings, we are preparing to engage with the FDA on the design of ALICE-3, our planned potentially registrational Phase III trial in first-line AML,” Dr. Buesa continued. “Our objective remains to initiate the study in 2027, subject to regulatory agreement and financing. Alongside our AML program, preliminary positive findings in accelerated/blast-phase myeloproliferative neoplasms and ongoing clinical evaluation in myelodysplastic syndromes are helping us explore the broader potential of iadademstat.”

“In CNS, we continue to advance the clinical development of vafidemstat across several indications,” Dr. Buesa added. “The Phase IIb trial in schizophrenia, EVOLUTION, continues to enroll patients across several European countries, and we expect to complete enrollment in spring 2027, with topline data anticipated by the end of 2027. This readout could represent an important inflection point for the company’s CNS program. The recent authorization of the HOPE-2 Phase II study in Phelan-McDermid syndrome marks another step forward for the program. In parallel, we are progressing with preparations for thePORTICO-2 Phase III trial in BPD and plan to request a Type C meeting with the FDA. Across our portfolio, we remain focused on disciplined execution, responsible allocation of resources and the continued strengthening of our intellectual property as we prepare for the next stages of clinical development.”

Third Quarter and Recent Highlights

Iadademstat:

  • Updated positive clinical data for iadademstat in hematological malignancies will be presented at the American Society of Hematology (ASH) 68th Annual Meeting, taking place December 12-15, 2026. Three abstracts, accepted for poster presentation, were published on November 4. A summary of the clinical data contained in the abstracts is provided below.
  • One of the ASH abstracts relates to the ongoing ALICE-2 (NCT06357182) Phase Ib clinical trial of iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed AML, sponsored by the Oregon Health & Science University (OHSU) Knight Cancer Institute. As reported in the abstract, the iadademstat-azacitidine-venetoclax triplet combination continued to show high remission rates, rapid responses and encouraging early survival with a manageable safety profile. As of the July 2026 data for ASH abstract submission, among evaluable patients (n=19), overall response rate (ORR) was 95%, including an 84% composite complete remission (CRc) rate and a 74% pure complete response (CR) rate. After median follow-up of 8 months, 12-month overall survival (OS) was 76%, with median OS not yet reached. In patients with ELN2022 intermediate- or adverse-risk disease, 12-month OS rates were 100% and 74%, respectively, with median OS not reached. Updated data with additional patients and more mature responses will be presented at the meeting.
  • Topline positive data from the Phase Ib FRIDA (NCT05546580) clinical trial of iadademstat in combination with gilteritinib in high-risk, heavily pre-treated patients with relapsed or refractory (R/R) FLT3-mutated AML were also published in a second ASH abstract. The iadademstat/gilteritinib combination demonstrated a manageable safety profile, similar to SoC treatment. The combination achieved a high composite complete remission rate of 67% (12/18) and a 31% 12-month survival rate at the recommended Phase 2 dose (RP2D).
  • Interim results from a Phase II study evaluating ASTX727 with or without iadademstat in patients with accelerated/blast-phase myeloproliferative neoplasms (NCT06661915) were also reported at an ASH abstract. This study is sponsored by the U.S. National Cancer Institute (NCI) and is conducted under the Cooperative Research and Development Agreement (CRADA) between Oryzon and the NCI. Based on data available as of the ASH 2026 abstract submission cut-off date, the combination of iadademstat and ASTX727 was well tolerated, with no dose-limiting toxicities (DLTs) observed. 50% of patients treated with the combination achieved acute leukemia response-partial (ALR-P) as best response. The trial continues in the dose escalation phase, and higher iadademstat dose level cohorts will be explored to inform the selection of a recommended Phase 2 dose of iadademstat for the randomized portion of the study.
  • VIVALDI, a new Phase Ib pilot study sponsored by CETLAM (Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplásicas), has been authorized in Spain. The study will evaluate iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed AML in subpopulations with poor responses to current standard-of-care treatment. CETLAM is a Spanish cooperative clinical research group that brings together specialists from leading hospitals in the research and treatment of acute myeloid leukemia and myelodysplastic syndromes. Oryzon is collaborating with CETLAM and supplying iadademstat for the study. This clinical study complements Oryzon’s planned ALICE-3 Phase III program in the U.S., and will provide operational experience relevant to the program’s future European arm.
  • Enrollment continued across ongoing iadademstat clinical studies in myelodysplastic syndromes (MDS, IIS-X005), essential thrombocythemia (IDEAL study), sickle cell disease (RESTORE study), and extensive-stage small cell lung cancer (ED-SCLC). These include studies conducted under the CRADA with the NCI, investigator-initiated studies (IIS), and Oryzon-sponsored trials. The company plans to share preliminary data from selected studies at future scientific meetings, subject to data availability and abstract acceptance.
  • Oryzon has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering combinations of iadademstat, or certain other LSD1 inhibitors, with gilteritinib and their use for the treatment of myeloid cancers, including AML. Once granted, the U.S. patent is expected to expire in 2042, excluding any potential patent term adjustment or patent term extension. 

Vafidemstat:

  • EVOLUTION Phase IIb trial of vafidemstat in schizophrenia continues to actively enroll patients. The study is primarily assessing its effects on negative symptoms, with cognitive impairment and positive symptoms included as secondary endpoints. Initially launched in Spain, EVOLUTION has been expanded to additional European countries (Bulgaria, Poland, Romania and Slovakia).
  • Oryzon continues preparations for the Phase III PORTICO-2 trial of vafidemstat in aggression in borderline personality disorder (BPD). Following FDA feedback, the Company is refining the trial protocol and conducting additional work to support the proposed clinical outcome measures ahead of resubmission. The company plans to request a type C meeting with the FDA by the end of 2026 or in the first quarter of 2027.
  • Oryzon has received approval to initiate the HOPE-2 Phase II study of vafidemstat for the treatment of Phelan-McDermid syndrome (PMS), a genetic disease associated with autism spectrum disorder. The study is a single-center, single-arm, open-label study and will be conducted in Spain. The primary objective of the study is to evaluate the safety and tolerability of vafidemstat in adults with PMS. Secondary objectives include assessing the effect of vafidemstat on anger and aggression and overall disease. The HOPE-2 study forms part of the activities supported by the Med4Cure IPCEI EU initiative.
  • Oryzon has continued to reinforce its IP portfolio for vafidemstat with new Decisions to Grant in South Korea and the Philippines for patent applications covering the use of vafidemstat for the treatment of non-aggressive symptoms of borderline personality disorder, in New Zealand for a patent application covering the use of vafidemstat for the treatment of aggression and social withdrawal, and in Mexico for a patent application covering the use of vafidemstat for the treatment of certain non-aggressive symptoms of autism spectrum disorder.

Earlier stage programs:

  • ORY-4001, Oryzon’s highly selective histone deacetylase 6 (HDAC6) inhibitor for neurological disorders, continues IND-enabling studies to enable future clinical trials. The program remains focused on potential applications in Amyotrophic Lateral Sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and other neurological disorders.

Financial Update: Third quarter 2026 Financial Results

Research and development (R&D) expenses were $4.6 million and $16.0 million for the quarter and nine months ended September 30th, 2026, compared to $3.9 and $9.6 million for the quarter and nine months ended September 30th, 2025.

General and administrative expenses were $1.0 and $3.8 million for the quarter and nine months ended September 30th, 2026, compared to $1.2 and $3.9 million for the quarter and nine months ended September 30th, 2025.

Net losses were $1.6 and $5.2 million for the quarter and nine months ended September 30th, 2026, compared to $1.2 and $4.6 million for the quarter and nine months ended September 30th, 2025. The result is as expected, given the biotechnology business model where companies in the development phase typically have a long-term maturation period for products and do not have recurrent income.

Negative net result was $3.0 million (–$0.04 per share) for the nine months ended September 30th, 2026, compared to a negative net result of $1.4 million (–$0.02 per share) for the nine months ended September 30th, 2025.

Cash, cash equivalents, and marketable securities totaled $21.7 million (€19.1 million) as of September 30, 2026.

       
ORYZON GENOMICS, S.A.
BALANCE SHEET DATA (UNAUDITED)1
(Amounts in thousands US $)
       
  September 30th, 2026   September 30th, 2025
       
Cash and cash equivalents 21,701   40,430
Marketable securities 0   0
Total Assets 169,496   172,341
       
Deferred revenue 0   0
Total Stockholders’ equity 147,977   138,279
       

             
ORYZON GENOMICS, S.A.
STATEMENTS OF OPERATIONS (UNAUDITED)1
(US $, amounts in thousands except per share data)
             
    Three Months Ended
September 30th
  Nine Months Ended
September 30th
     
    2026 2025   2026 2025
             
Collaboration Revenue   0 0   0 0
             
Operating expenses:            
Research and Development   4,623 3,857   15,968 9,627
General and administrative   1,007 1,232   3,812 3,890
             
Total operating expenses   5,630 5,089   19,780 13,517
             
Loss from Operations   -5,630 -5,089   -19,780 -13,517
             
Other income, net   3,981 3,894   14,582 8,879
             
Net Loss   -1,649 -1,195   -5,198 -4,638
             
Net Financial & Tax   233 1,613   2,228 3,243
             
Net Result   -1,416 418   -2,970 -1,395
             
             
Loss per share allocable to common stockholders:        
Basic   -0.02 0.01   -0.04 -0.02
             
Weighted average Shares outstanding            
Basic   81,921,612 75,197,026   79,000,488 72,523,994
             
1 Spanish GAAP            
* Exchange Euro/Dollar (1.1355 for 2026 and 1.1741 for 2025)        

About Oryzon
Founded in 2000 and headquartered in Barcelona, Spain, Oryzon (ISIN: ES0167733015) is a clinical-stage biopharmaceutical company and a European leader in epigenetics, with a strong focus on personalized medicine for central nervous system (CNS) disorders and oncology. Oryzon’s team comprises highly experienced pharmaceutical professionals based in Barcelona, Boston, and New Jersey. The Company has an advanced clinical portfolio built around two LSD1 inhibitors: iadademstat, its oncology/hematology program, which is being evaluated in several ongoing Phase I and II studies and has demonstrated strong preliminary clinical activity in acute myeloid leukemia, including a 95% overall response rate (ORR) in first-line AML; and vafidemstat, its lead CNS program, which is Phase III–ready in borderline personality disorder (BPD). In addition, Oryzon is advancing a broader epigenetics pipeline targeting other mechanisms, including HDAC6, for which the Company has nominated ORY-4001 as a clinical candidate for potential development in Charcot–Marie–Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and other neurological disorders. The Company also operates a robust platform for biomarker identification and target validation across malignant and neurological diseases. For more information, visit www.oryzon.com

About Iadademstat
Iadademstat (ORY-1001) is an oral, highly selective inhibitor of the epigenetic enzyme LSD1, with potent differentiating effect in hematologic cancers. Iadademstat has shown encouraging safety and strong clinical activity in combination with azacitidine in a Phase IIa trial in elder 1L acute myeloid leukemia (AML) patients (ALICE trial). Iadademstat is currently being evaluated in combination with azacitidine and venetoclax in 1L AML in the ALICE-2 trial, an investigator-initiated study (IIS) led by OHSU, and in combination with gilteritinib in the company-sponsored Phase Ib FRIDA trial in relapsed/refractory FLT3-mutant AML, with highly encouraging preliminary safety and efficacy data reported in both trials: 95% overall response rate (ORR) and 84% composite complete remission rate (CRc), with 74% strict CR in 1L AML, and 67% CRc in R/R Flt3-mut AML (as per ASH 2026 abstracts). Subject to positive final data in the ALICE-2 study, the company has announced plans to conduct a potentially registrational study in 1L AML. Additional studies in hematologic malignancies include an IIS in myelodysplastic syndrome (MDS) and National Cancer Institute (NCI)-sponsored trials in myeloproliferative neoplasms and 1L AML conducted under the Cooperative Research and Development Agreement (CRADA) between Oryzon and the NCI. Beyond hematological cancers, iadademstat is being evaluated in extensive stage small cell lung cancer (ED-SCLC) in a Phase I/II randomized trial in 1L in combination with immune checkpoint inhibition (ICI) sponsored by NCI and led by the Memorial Sloan Kettering Cancer Center, and an IIS trial in combination with ICI and radiotherapy. Oryzon has also expanded iadademstat into non-oncological hematology indications, with ongoing trials in sickle cell disease and essential thrombocythemia. Iadademstat has orphan drug designation for AML in the US and EU and for SCLC in the US.

About Vafidemstat
Vafidemstat (ORY-2001) is an oral, CNS-optimized LSD1 inhibitor with the potential to address psychiatric and neurodevelopmental disorders through epigenetic modulation. In preclinical studies, vafidemstat has demonstrated effects on cognition, neuroinflammation, aggression, and social behavior, as well as neuroprotective and anti-inflammatory activity across multiple CNS disease models. Oryzon has completed several Phase II clinical trials with vafidemstat, including the REIMAGINE and REIMAGINE-AD trials in aggression in patients with different psychiatric disorders and in aggressive/agitated patients with moderate or severe AD, respectively, with positive clinical results reported in both trials. Following completion of the global randomized double-blind Phase IIb PORTICO trial in borderline personality disorder (BPD), vafidemstat is advancing towards Phase III development for the treatment of aggression in BPD, with a Phase III trial currently in preparation. Vafidemstat is also being evaluated in the ongoing double-blind, randomized, placebo-controlled Phase IIb EVOLUTION trial in schizophrenia, targeting negative symptoms. In addition, Oryzon is deploying a CNS precision medicine approach with vafidemstat in genetically defined patient subpopulations of certain CNS disorders, as well as in neurodevelopmental syndromes, including the recently approved HOPE-2 clinical trial in Phelan-McDermid Syndrome.

FORWARD-LOOKING STATEMENTS  
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any person acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.

Spain  Oryzon  IR & Media, Europe & US  
Patricia Cobo/Mario Cordera  Emili Torrell  Sandya von der Weid   
Atrevia  Chief BD Officer  LifeSci Advisors, LLC   
+34 91 564 07 25 +34 93 515 1313  +41 78 680 05 38    
+34 673 33 97 65       
pcobo@atrevia.com  
mcordera@atrevia.com  
etorrell@oryzon.com   svonderweid@lifesciadvisors.com    

10 November 2026

HARGREAVE HALE AIM VCT PLC
(the “Company”)

NAV announcement

As at close of business on 6 November 2026, the unaudited Net Asset Value (NAV) for Hargreave Hale AIM VCT plc was as follows:

NAV per Ordinary share of 1p – 32.35 pence.

END

For further information, please contact:

Canaccord Genuity Asset Management Limited
Abbe Martineau
aimvct@canaccord.com
+44 20 7523 4525
 

LEI: 213800LRYA19A69SIT31 

Paris, November 10th, 2026

The disclosure of share transactions carried out from November 2nd to November 6th, 2026, was sent to the AMF on November 10th, 2026. As required by current law, this document is publically available and can be consulted on the Company’s website (www.lvmh.com) under the section «regulated information».

LVMH

LVMH Moët Hennessy Louis Vuitton is represented in Wines and Spirits by a portfolio of brands that includes Moët & Chandon, Dom Pérignon, Veuve Clicquot, Krug, Ruinart, Mercier, Château d’Yquem, Domaine du Clos des Lambrays, Château Cheval Blanc, Colgin Cellars, Hennessy, Glenmorangie, Ardbeg, Belvedere, Woodinville, Volcán de mi Tierra, Chandon, Cloudy Bay, Terrazas de los Andes, Cheval des Andes, Bodega Numanthia, Ao Yun, Château d’Esclans, Château Galoupet, Joseph Phelps and Château Minuty. Its Fashion and Leather Goods division includes Louis Vuitton, Christian Dior, Celine, Loewe, Kenzo, Givenchy, Fendi, Emilio Pucci, Berluti, Loro Piana, RIMOWA, Barton Perreira and Vuarnet. LVMH is present in the Perfumes and Cosmetics sector with Parfums Christian Dior, Guerlain, Parfums Givenchy, Kenzo Parfums, Perfumes Loewe, Benefit Cosmetics, Make Up For Ever, Acqua di Parma, Fresh, Fenty Beauty by Rihanna, Maison Francis Kurkdjian and Officine Universelle Buly. LVMH’s Watches and Jewelry division comprises Bulgari, TAG Heuer, Tiffany & Co, Chaumet, Zenith, Fred, Hublot and l’Epée. LVMH is also active in Selective Retailing as well as in other activities through DFS, Sephora, Le Bon Marché, La Samaritaine, Groupe Les Echos-Le Parisien, Paris Match, Cova, Le Jardin d’Acclimatation, Royal Van Lent, Belmond and Cheval Blanc hotels.

LVMH CONTACTS

Analysts and investors
Rodolphe Ozun
LVMH
+ 33 1 44 13 27 21
Media
Jean-Charles Tréhan
LVMH
+ 33 1 44 13 26 20
MEDIA CONTACTS  
France
Charlotte Mariné / +33 6 75 30 43 91
Axelle Gadala / +33 6 89 01 07 60
Publicis Consultants
+ 33 1 44 82 46 05
France
Michel Calzaroni / + 33 6 07 34 20 14
Olivier Labesse / Hugues Schmitt / Thomas Roborel de Climens / + 33 6 79 11 49 71
Italy
Michele Calcaterra / Matteo Steinbach
SEC and Partners
+ 39 02 6249991
UK
Hugh Morrison / Charlotte McMullen
Montfort Communications
+ 44 7921 881 800
US
Nik Deogun / Blake Sonnenshein
Brunswick Group
+ 1 212 333 3810
China
Daniel Jeffreys
Deluxewords
+ 44 772 212 6562
+ 86 21 80 36 04 48

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.